Rheumatology International, Journal Year: 2024, Volume and Issue: 44(9), P. 1733 - 1737
Published: March 29, 2024
Language: Английский
Rheumatology International, Journal Year: 2024, Volume and Issue: unknown
Published: Oct. 8, 2024
Language: Английский
Citations
3
Lara D. Veeken, Journal Year: 2024, Volume and Issue: unknown
Published: Aug. 6, 2024
Abstract Objectives There are limited real-life data regarding the efficacy and safety of rituximab (RTX) as a remission maintenance agent in microscopic polyangiitis (MPA) granulomatosis-with-polyangiitis (GPA). We aimed to estimate incidence risk factors for relapses, well serious adverse events (SAEs) MPA/GPA patients during RTX maintenance. Methods A retrospective cohort newly diagnosed/relapsing GPA/MPA who received (≥1 cycle, ≥6 months follow-up) following complete (BVAS version-3 = 0 plus prednisolone ≤7.5 mg/day) with induction regimens. SAEs included infections, COronaVIrus-Disease 2019 (COVID-19)–associated hospitalizations, deaths, cardiovascular events, malignancies hypogammaglobulinemia. The rates (IRs) relapse-free survival were estimated through Kaplan–Meier plots. Cox regression was conducted investigate associated time-to-relapse. Results total 101 included: 48% females, 69% GPA, 53% diagnosed, median age 63 years. During follow-up (294.5 patient-years, median: 3 cycles), 30 relapses (57% major) occurred among 24 (24%, IR 10.2/100 patient-years). Kidney involvement (adjusted hazard ratio/aHR: 0.20; 95% CI: 0.06–0.74, P 0.016), prior CYC (vs monotherapy: aHR 0.02; 0.001–0.43, 0.012) shorter time interval until (aHR 1.07; 1.01–1.14, 0.023) decreased relapse risk. recorded 17 infections (IR 5.8/100 patient-years), 11 COVID-19–associated hospitalizations 3.7/100 4 1.4/100 6 2/100 patient-years) 10 deaths 3.4/100 Conclusion In this real-world study, approximately 1 out patients. involvement, CYC, earlier achievement lower rate consistent previous reports, whereas an increased observed.
Language: Английский
Citations
2
BMC Psychology, Journal Year: 2024, Volume and Issue: 12(1)
Published: Aug. 8, 2024
Since January 8, 2023, China has managed COVID-19 as a Class-B infectious disease, marking the epidemic's transition to low-level stage. This study analyzes relationship between public's perceived community with shared future for doctor-patient (PCSF), health self-consciousness, benefit finding, and anxiety in this Additionally, it compares changes these variables across different stages of COVID-19.
Language: Английский
Citations
1
Medical alphabet, Journal Year: 2024, Volume and Issue: 31, P. 31 - 38
Published: Jan. 13, 2024
Aim . To conduct a comparative analysis of the course new coronavirus infection (NCI) and post-Covid syndrome (PCS) caused by Omicron strain earlier strains in patients with rheumatic diseases (RD). Materials methods 271 NCI were included study. For Covid-19 PCS, two periods defined: first period was from March 2020 to December 2021 – early strains, 2nd appearance strain. In analysed group, there 214 (79 %) people who had 57 (21 Omicron. A assessment presence PCS its characteristics carried out 3, 6, 9, 12 months after Covid-19. Results Among underwent CT-verified lung damage recorded more often, which determined higher frequency hospitalizations. At same time, onset presented such symptoms as general weakness, lack taste smell; oftener bothered periodic sensations heat, increased body temperature, shortness breath. group strain, comorbid pathology oftener. groups occurred 50.8% 33.3%, respectively. both groups, musculoskeletal manifestations remained most common, depression being commoner strains. The complaints characteristic at high level for 6 months, downward trend noted 9th month An increase RD activity found 3 groups. Conclusions moderate severe disease, well development PCD within common. between decreased follow-up. observed Covid-19, regardless transferred tendency decrease 9 NCI.
Language: Английский
Citations
0
Egyptian Journal of Bronchology, Journal Year: 2024, Volume and Issue: 18(1)
Published: Oct. 1, 2024
Abstract Background The causal agent in a lower respiratory tract sample was identified as severe acute syndrome coronavirus-2 (SARS-CoV-2). Objective To evaluate the vaccinated and unvaccinated persons for signs severity of SARS-CoV-2. Patients methods This retrospective analysis included 99 cases ranging age from 25 to 65 with history SARS-CoV-2 infection confirmed by polymerase chain reaction (PCR). We compared incidence COVID-19 between non-vaccinated groups variety outcomes. performed following tests on all cases: blood pressure, pulse rate, oxygen saturation, PCR, CBC, CRP, ferritin, D-dimer. Results In terms severity, 60.6% are moderate category, 13.1% critical level. Among group, 47.2% had lung symptoms, 22.2% group ( p = 0.001). mix pulmonary extrapulmonary symptoms. A significant difference groups: 36 (100%) CT, 26 (96.3%) two-dose cases, 30 (83.3%) three-dose cases. Conclusion provided proof that vaccine recipients reduced CT ratings elevated inflammatory markers those individuals who were not given vaccines. Cases immunized saturation levels.
Language: Английский
Citations
0
Rheumatic Disease Clinics of North America, Journal Year: 2024, Volume and Issue: 51(1), P. 45 - 59
Published: Oct. 18, 2024
Language: Английский
Citations
0
Clinical Immunology, Journal Year: 2023, Volume and Issue: 259, P. 109879 - 109879
Published: Dec. 22, 2023
Language: Английский
Citations
1
Rheumatology International, Journal Year: 2024, Volume and Issue: 44(9), P. 1733 - 1737
Published: March 29, 2024
Language: Английский
Citations
0